Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSD-102
- Development stage
- Unknown
- Lead developer
- Mindstate Design Labs
- Modality
- Small Molecules
01
Overview
MSD-102 is an investigational small molecule fixed-dose combination drug candidate being developed by Mindstate Design Labs. It is designed as part of the company's ASSURANCE psychoactive-effect program, which aims to demonstrate the de novo synthesis of novel psychoactive effects. Developed using Mindstate's proprietary Osmanthus neuroengineering platform, MSD-102 combines a psychedelic 'primer' compound with a non-psychedelic 'probe' compound to target specific conscious states. The candidate is currently in Phase 1b/2a clinical development, though its specific molecular targets and therapeutic indications remain undisclosed.
- Other names
- ASSURANCE arm
Beyond the preview
Go deeper on MSD-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSD-102.